Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins

Peptides

Volumn 63, Issue , 2015, Pages 10-21

  Verbeken, Mathieu ^a   Wynendaele, Evelien ^a   Mauchauffée, Elodie ^b   Bracke, Nathalie ^a   Stalmans, Sofie ^a   Bojnik, Engin ^c   Benyhe, Sandor ^c   Peremans, Kathelijne ^a   Polis, Ingeborgh ^a   Burvenich, Christian ^a   Gjedde, Albert ^d   Hernandez, Jean Franҫois ^b   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antinociceptive activity; Blood brain barrier (BBB) transport; In vivo mouse models; Influx efflux; Linear cyclic enkephalin analogs

Indexed keywords

ENKEPHALIN; METHYLGUANIDINE; MORPHINE; MU OPIATE RECEPTOR; THIOUREA; ANALGESIC AGENT;

ANIMAL TISSUE; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; CYCLIZATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION CONSTANT; MALE; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; HALF LIFE TIME; IC50; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NOCICEPTION; NOCICEPTIVE PAIN; PRECLINICAL STUDY; WISTAR RAT;

MUS;

ANALGESICS; ANIMALS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; DRUG EVALUATION, PRECLINICAL; ENKEPHALINS; HALF-LIFE; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENTRICULAR; MALE; METHYLGUANIDINE; MICE, INBRED ICR; NOCICEPTION; NOCICEPTIVE PAIN; RATS, WISTAR; THIOUREA;

EID: 84919724778     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.10.010     Document Type: Article

References (67)

1. Abbruscato TJ, Thomas SA, Hruby VJ, Davis TP. Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. J Neurochem 1997;69:1236-45.
2. Arnold AP, Etgen AM, Fahrbach SE, Rubin RT. Hormones, brain and behavior, five-volume set. Academic Press; 2002.
3. Banks W. Drug transport into the central nervous system: using newer findings about the blood-brain barriers. Drug Deliv Transl Res 2012;2:152-9.
4. Banks WA, Audus KL, Davis TP. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 1992;13:1289-94.
5. Banks WA, Kastin AJ. Interactions between the blood-brain barrier and endogenous peptides: emerging clinical implications. Am J Med Sci 1988;295:459-65.
6. Banks WA, Kastin AJ. Peptide transport systems for opiates across the blood-brain barrier. Am J Physiol 1990;259:E1-10.
7. Banks WA, Kastin AJ. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 1985;15:287-92.
8. Banks WA, Kastin AJ. The role of the blood-brain barrier transporter PTS-1 in regulating concentrations of methionine enkephalin in blood and brain. Alcohol 1997;14:237-45.
9. Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996;48:136-46.
10. Boje KMK. In vivo measurement of blood-brain barrier permeability. Current protocols in neuroscience. John Wiley & Sons, Inc.; 2001.
11. Bojnik E, Magyar A, Toth G, Bajusz S, Borsodi A, Benyhe S. Binding studies of novel, non-mammalian enkephalins, structures predicted from prog and lung-fish brain cDNA sequences. Neuroscience 2009;158:867-74.
12. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009;87:212-51.
13. Brownson EA, Abbruscato TJ, Gillespie TJ, Hruby VJ, Davis TP. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther 1994;270:675-80.
14. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res 2008;41:1331-42.
15. Chatterjee J, Rechenmacher F, Kessler H. N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl 2013;52:254-69.
16. Chen W, Yang JZ, Andersen R, Nielsen LH, Borchardt RT. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model. J Pharmacol Exp Ther 2002;303:849-57.
17. Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 1994;11:412-9.
18. Condamine E, Leprince J, Suaudeau C, Mayer C, Davoust D, Costentin J, et al. The proenkephalin A-processing product peptide E, which encompasses two enkephalin sequences, has a much lower opioid activity than beta-endorphin. Peptides 1999;20:865-71.
19. Costa E, Mocchetti I, Supattapone S, Snyder SH. Opioid peptide biosynthesis: enzymatic selectivity and regulatory mechanisms. FASEB J 1987;1:16-21.
20. Dagenais C, Ducharme J, Pollack GM. Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett 2001;301:155-8.
21. Dandekar S, Sabol SL. Cell-free translation and partial characterization of mRNA coding for enkephalin-precursor protein. Proc Natl Acad Sci USA 1982;79:1017-21.
22. De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. Anal Biochem 2008;376:229-34.
23. Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997;18:1431-9.
24. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005;2:44-53.
25. Egleton RD, Davis TP. Transport of the delta-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis1. J Pharm Sci 1999;88:392-7.
26. Egleton RD, Mitchell SA, Huber JD, Janders J, Stropova D, Polt R, et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res 2000;881:37-46.
27. Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther 2001;299:967-72.
28. Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS J 2005;7:E852-6.
29. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res 1982;257:237-74.
30. Gjedde A. High- and low-affinity transport of d-glucose from blood to brain. J Neurochem 1981;36:1463-71.
31. Gjedde A, Bauer WR, Wong DF. Neurokinetics: the dynamics of neurobiology in vivo, Springer US; 2011, http://dx.doi.org/10.1007/978-1-4419-7409-9
32. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993;47:169-76.
33. Hamze A, Gandreuil C, Lisowski V, Andureu F, Fulcrand P, Martinez J, et al. Solid phase synthesis of mono- or disubstituted arginine containing peptides from an isothiocitrulline precursor. Tetrahedron Lett 2005;46:7349-53.
34. Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 2012;17:1224-32.
35. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004;4:1-17.
36. Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J. Development of opioid peptide analogs for pain relief. Curr Pharm Des 2010;16:1126-35.
37. Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, et al. Round and round we go: cyclic peptides in disease. Curr Med Chem 2006;13:2221-32.
38. Luttinger D. Determination of antinociceptive efficacy of drugs in mice using different water temperatures in a tail-immersion test. J Pharmacol Methods 1985;13:351-7.
39. Newton P, Harrison P, Clulow S. A novel method for determination of the affinity of protein: Protein interactions in homogeneous assays. J Biomol Screen 2008;13:674-82.
40. Novoa A, Van Dorpe S, Wynendaele E, Spetea M, Bracke N, Stalmans S, et al. Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: effect on opioid activity and biodistribution. J Med Chem 2012;55:9549-61.
41. Pan WH, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553-61.
42. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 1991;259:66-70.
43. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
44. Rousselle C, Clair P, Smirnova M, Kolesnikov Y, Pasternak GW, Gac-Breton S, et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J Pharmacol Exp Ther 2003;306:371-6.
45. Saladin PM, Zhang BD, Reichert JM. Current trends in the clinical development of peptide therapeutics. IDrugs 2009;12:779-84.
46. Sewell RDE, Spencer PSJ. Antinociceptive activity of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats. Neuropharmacology 1976;15:683-8.
47. Shechter Y, Heldman E, Sasson K, Bachar T, Popov M, Fridkin M. Delivery of neuropeptides from the periphery to the brain: studies with enkephalin. ACS Chem Neurosci 2010;1:399-406.
48. Simon J, Benyhe S, Abutidze K, Borsodi A, Szucs M, Toth G, et al. Kinetics and physical parameters of rat-brain opioid receptors solubilized by digitonin and chaps. J Neurochem 1986;46:695-701.
49. Stalmans S, Wynendaele E, Bracke N, Knappe D, Hoffmann R, Peremans K, et al. Blood-brain barrier transport of short proline-rich antimicrobial peptides. Protein Pept Lett 2014;21:399-406.
50. Svenson J, Vergote V, Karstad R, Burvenich C, Svendsen JS, De Spiegeleer B. Metabolic fate of lactoferricin-based antimicrobial peptides: effect of truncation and incorporation of amino acid analogs on the in vitro metabolic stability. J Pharmacol Exp Ther 2010;332:1032-9.
51. Touati-Jallabe Y, Bojnik E, Legrand B, Mauchauffée E, Chung NN, Schiller PW, et al. Cyclic enkephalins with a diversely substituted guanidine bridge or a thiourea bridge: synthesis, biological and structural evaluations. J Med Chem 2013;56:5964-73.
52. Touati-Jallabe Y, Chiche L, Hamze A, Aumelas A, Lisowski V, Berthomieu D, et al. Cyclic peptides with a diversely substituted guanidine bridge: solid-phase synthesis and structural analysis. Chem Eur J 2011;17:2566-70.
53. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 1990;54:1882-8.
54. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005;2:54-62.
55. Van Dorpe S, Adriaens A, Polis I, Peremans K, Van Bocxlaer J, De Spiegeleer B. Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides. Peptides 2010;31:1390-9.
56. Van Dorpe S, Bronselaer A, Nielandt J, Stalmans S, Wynendaele E, Audenaert K, et al. Brainpeps: the blood-brain barrier peptide database. Brain Struct Funct 2012;217:687-718.
57. Verbeken M, Wynendaele E, Lefebvre RA, Goossens E, Spiegeleer BD. The influence of peptide impurity profiles on functional tissue-organ bath response: the 11-mer peptide INSL6[151-161] case. Anal Biochem 2012;421:547-55.
58. Vergote V, Baert B, Vandermeulen E, Peremans K, van Bree H, Slegers G, et al. LC-UV/MS characterization and DOE optimization of the iodinated peptide obestatin. J Pharm Biomed Anal 2008;46:127-36.
59. Vergote V, Bode S, Peremans K, Vanbree H, Baert B, Slegers G, et al. Analysis of iodinated peptides by LC-DAD/ESI ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;850:213-20.
60. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 2008;29:1740-8.
61. Weber SJ, Abbruscato TJ, Brownson EA, Lipkowski AW, Polt R, Misicka A, et al. Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. J Pharmacol Exp Ther 1993;266:1649-55.
62. Witt KA, Davis TP. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J 2006;8:E76-88.
63. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001;22:2329-43.
64. Witt KA, Huber JD, Egleton RD, Davis TP. Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. J Pharmacol Exp Ther 2000;295:972-8.
65. Witt KA, Slate CA, Egleton RD, Huber JD, Yamamura HI, Hruby VJ, et al. Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin. J Neurochem 2000;75:424-35.
66. Wong DF, Gjedde A, Wagner Jr HN. Quantification of neuroreceptors in the living human brain I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:137-46.
67. Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res 1985;336:125-32.